Support: 888-992-3836
Copyright © 2023 InvestorsHub Inc.
Replies to post #241492 on Avid Bioservices Inc (CDMO)
nuke661
11/04/15 3:46 PM
#241495 RE: asmarterwookie #241492
While patients who received Opdivo lived longer than those who received docetaxel across the study, an evaluation of samples from a subgroup of patients’ tumors suggests that the level of PD-L1 expression in NSCLC tumors may help identify patients who are more likely to live longer due to treatment with Opdivo. Therefore, today the FDA also approved the PD-L1 IHC 28-8 pharmDx test to detect PD-L1 protein expression levels and help physicians determine which patients may benefit most from treatment with Opdivo.